Jacobs Journal of Bone Marrow and Stem Cell Research

Response of the Bone Marrow Stromal Cells to Osteogenic Drugs in Patients Undergoing Primary Total Hip Arthroplasty

Published on: 2018-12-03


Implant osseointegration relies on the interplay of implant surface and the surrounding bone cells. The purpose of this study was to investigate the in vitro response of the bone marrow stromal cells (BMSCs) to osteogenic drugs in patients undergoing primary total hip arthroplasty (THA). Bone marrow aspirates were obtained from the discarded femoral head in 13 THA patients. The number of STRO-1 and bone morphogenetic protein receptor (BMPR)-expressing cells were measured by flow cytometry. Real-time PCR was used to measure expression of osteogenic relevant genes of BMSCs. Osteogenic potential was evaluated by alkaline phosphatase (ALP) activity. The response of BMSCs to osteogenic drugs (BMP-2, dexamethasone and etidronate) was further evaluated. There was a strong association between the gene levels of BMPR1a, ALP, RunX-2 and MSX2 with the percent of STRO-1+ cells. BMP-2 (100 ng/ml) stimulated the BMPR-pSMAD1/5 signaling pathway. Both etidronate (250 ng/ml) and dexamethasone (10 nM) treatments raised ALP activity in 33% and 70% of BMSC samples, respectively. This was independent of the activation of pSMAD signaling. A better understanding of the individual variations of BMSCs in response to osteogenic drugs is important for the THA patient management and the strategic plan of implant surface drug delivery


Bone Marrow Mesenchymal Stromal Cells; Total Hip Arthroplasty; Osseointegration; Bone Morphogenetic Protein; Flow Cytometry; Alkaline Phosphatase (ALP)